2023 article

2022 White Paper on Recent Issues in Bioanalysis: Enzyme Assay Validation, BAV for Primary End Points, Vaccine Functional Assays, Cytometry in Tissue, LBA in Rare Matrices, Complex NAb Assays, Spectral Cytometry, Endogenous Analytes, Extracellular Vesicles Part 2 – Recommendations on Biomarkers/CDx, Flow Cytometry, Ligand-Binding Assays Development & Validation; Emerging Technologies; Critical Reagents Deep Characterization

Giane Sumner, Steve A. Keller, James W. Huleatt, Roland F. Staack, Leslie Wagner, Mitra Azadeh, Abbas Bandukwala, Liching Cao, Xiulian Du, Gabriela Salinas, Fabio Garofolo, Shannon Harris, Shirley Hopper, Chad R. Irwin, Qin C. Ji, Julie Joseph, Lindsay King, Arvind G. Kinhikar, Lu Yang, Rosa Luo, Omar S. Mabrouk, Ludovic Malvaux, Jean‐Claude Marshall, Kristina McGuire, Vincent Mikol, Robert J. Neely, Xiazi I Qiu, Yoshiro Saito, Bruno Salaun, Ingrid Lea Scully, John Smeraglia, Therese Solstad, Jeroen N. Stoop, Huaping Tang, Priscila Camillo Teixeira, Yixin Wang, M.T. Wright, Luis Mendez, Chris Beaver, Jacqueline Eacret, Amelia Au‐Yeung, Vilma Decman, Francis J. Dessy, Steven Eck, Polina Goihberg, Enrique Gomez Alcaide, Christèle Gonneau, Katharine D. Grugan, Michael Nathan Hedrick, Sumit Kar, Sarita Sehra, Erin Stevens, Chad R. Stevens, Yongliang Steve Sun, Fred McCush, LaKenya Williams, Sally K. Fischer, Bonnie Wu, Gregor Jordan, C. R. Burns, Isabelle Cludts, Kelly Coble, Christine M. Grimaldi, Neil Henderson, Alison P. Joyce, Gregor P. Lotz, Yanmei Lu, Linlin Luo, Florian Neff, Gizette V. Sperinde, Kay‐Gunnar Stubenrauch, Yuting Wang, Mark Ware, Weifeng Xu

15Citations signalées, ce qui n’est pas une note de qualité

28Institutions déclarées

8Pays d’affiliation déclarés

Rattachement africain : us, de, nl, ca, be, fr, gb, se. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

The 16th Workshop on Recent Issues in Bioanalysis (16th WRIB) took place in Atlanta, GA, USA on September 26–30, 2022. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest in bioanalysis. The 16th WRIB included 3 Main Workshops and 7 Specialized Workshops that together spanned 1 week in order to allow exhaustive and thorough coverage of all major issues in bioanalysis, biomarkers, immunogenicity, gene therapy, cell therapy and vaccines. Moreover, in-depth workshops on ICH M10 BMV final guideline (focused on this guideline training, interpretation, adoption and transition); mass spectrometry innovation (focused on novel technologies, novel modalities, and novel challenges); and flow cytometry bioanalysis (rising of the 3rd most common/important technology in bioanalytical labs) were the special features of the 16th edition. As in previous years, WRIB continued to gather a wide diversity of international, industry opinion leaders and regulatory authority experts working on both small and large molecules as well as gene, cell therapies and vaccines to facilitate sharing and discussions focused on improving quality, increasing regulatory compliance, and achieving scientific excellence on bioanalytical issues. This 2022 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2022 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 2) covers the recommendations on LBA, Biomarkers/CDx and Cytometry. Part 1 (Mass Spectrometry and ICH M10) and Part 3 (Gene Therapy, Cell therapy, Vaccines and Biotherapeutics Immunogenicity) are published in volume 15 of Bioanalysis, issues 16 and 14 (2023), respectively.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.

Titre Crossref: 2022 White Paper on Recent Issues in Bioanalysis: Enzyme Assay Validation, BAV for Primary End Points, Vaccine Functional Assays, Cytometry in Tissue, LBA in Rare Matrices, Complex NAb Assays, Spectral Cytometry, Endogenous Analytes, Extracellular Vesicles <u>Part 2</u> – Recommendations on Biomarkers/CDx, Flow Cytometry, Ligand-Binding Assays Development & Validation; Emerging Technologies; Critical Reagents Deep Characterization
Date Crossref: 01/08/2023
Éditeur: Informa UK Limited
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Regeneron (United States) pays non établi dans la notice
Entreprise
AbbVie (United States) pays non établi dans la notice
Entreprise
Sanofi (United States) pays non établi dans la notice
Entreprise
Roche Pharma AG (Germany) pays non établi dans la notice
Entreprise
United States Food and Drug Administration pays non établi dans la notice
Organisme public
Alkermes (United States) pays non établi dans la notice
Entreprise
Sangamo BioSciences (United States) pays non établi dans la notice
Entreprise
Janssen (Netherlands) pays non établi dans la notice
Entreprise
Health Canada pays non établi dans la notice
Organisme public
Pfizer (United States) pays non établi dans la notice
Entreprise
Novartis (United States) pays non établi dans la notice
Entreprise
Crinetics Pharmaceuticals (United States) pays non établi dans la notice
Entreprise

Regeneron (United States), AbbVie (United States) et Sanofi (United States), avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Biosimilars and Bioanalytical MethodsSARS-CoV-2 detection and testing

Consulter la publication primaire Ouvrir le DOI